Compounds > maprotiline

maprotiline and naltrexone

maprotiline has been researched along with naltrexone in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (18.18)	18.2507
2000's	5 (45.45)	29.6817
2010's	4 (36.36)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Mendez, M; Miranda, HF; Pinardi, G; Sierralta, F	1
Gray, AM; Sewell, RD; Spencer, PS	1
Brenneman, D; Crooke, J; Malatynska, E; Pinhasov, A; Rosenthal, D	1

Reviews

1 review(s) available for maprotiline and naltrexone

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

10 other study(ies) available for maprotiline and naltrexone

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:3 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations	2002
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Interaction of opioids with antidepressant-induced antinociception. Psychopharmacology, 1995, Volume: 122, Issue:4 Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Clomipramine; Drug Combinations; Female; Imipramine; Male; Maprotiline; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Pain Measurement; Random Allocation; Selective Serotonin Reuptake Inhibitors; Zimeldine	1995
The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. British journal of pharmacology, 1998, Volume: 124, Issue:4 Topics: Abdominal Muscles; Acetic Acid; Amitriptyline; Analgesics; Animals; Antidepressive Agents; Cyclobutanes; Dothiepin; Male; Maprotiline; Mice; Muscle Contraction; Naloxone; Naltrexone; Narcotic Antagonists; Neprilysin; Neurotransmitter Uptake Inhibitors; Opioid Peptides; Pain Measurement; Paroxetine; Protease Inhibitors; Receptors, Opioid; Selective Serotonin Reuptake Inhibitors; Thiorphan	1998
Reduction of Submissive Behavior Model for antidepressant drug activity testing: study using a video-tracking system. Behavioural pharmacology, 2005, Volume: 16, Issue:8 Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Competitive Behavior; Dominance-Subordination; Feeding Behavior; Fluoxetine; Imipramine; Maprotiline; Mice; Naltrexone; Narcotic Antagonists; Rats	2005